Search academic texts

Information × Registration Number 0219U003080, 0117U001047 , R & D reports Title Defining the role of molecular biomarkers in assessing the aggressiveness of uterine sarcoma popup.stage_title Head Sukhina O.M., Simonova-Pushkar L.I., Registration Date 18-01-2019 Organization State Organization "Grigoriev Institute for Medical Radiologiy of the National Academy of Medical Sciences of Ukraine" popup.description2 Object of study: combined treatment of uterine sarcomas, molecular and biological characteristics of the tumor. Objective: to increase the efficiency of diagnostics, treatment and prognosis of uterine sarcoma through the determination of the role of some molecular biological characteristics of aggressiveness of uterine sarcoma for the individualization of therapy. Methods and apparatus: roentgenological, morphological, clinical, instrumental, statistical; universal dosimeter UNIDOS-E, ultrasound diagnostic system VOLUSON E8 Expert. Theoretical and practical results: The role of matrix metalloproteinase-9 (MMP-9) and its tissue inhibitor (TIMP) in patients with uterine fibroids and uterine sarcoma was evaluated and shown that the level of MMP-9 in blood serum of patients with uterine sarcoma to be moderate, but with a possible excess of the index in patients with benign tumors in 1.1 times. An analysis of the expression level of MMP-9 in uterine fibroids showed its extremely low level. The mp53 and MMP-9 co-expression was established - the mp53 median has increased 2-fold with the growth of the MMP-9 expression. The unfavorable course of undifferentiated sarcoma is observed with hyperexpression of mp53 even with moderate expression of MMP-9, in leiomyosarcoma - at the marked expression level of MMP-9 even in the absence of mp53, in endometrial stromal sarcoma, on the contrary, with hyperexpression of mp53 in the practical absence of expression of MMP-9. Novelty: It was established that conducting radiotherapy according to the developed method in the combination treatment scheme provides local control and a probable decrease in the frequency of metastases from 66.7 to 11.8 %. The possibility of using the level of MMP and TIMP in blood plasma for treatment monitoring and observation of patients with uterine sarcoma was determined. The effectiveness of implementation: the absence of adjuvant CTx during six hospitalizations allows saving about 15 thousand UAH for one patient. Field of use: oncology, radiology. Product Description popup.authors Гертман В.З. Грановська Г.І. Долгая О.В. Задніпровська Н.О. Коломацька В.В. Кругова І.М. Лисенко В.Н. Ляховська Н.В. Насонова А.М. Немальцова К.В. Пушкар О.С. Радченко О.А. Сімонова-Пушкар Л.І. Сплюхина О.В. Сухін В.С. Сухіна О.М. Федоренко К.С. Шустов І.Б. Яковенко К.В. popup.nrat_date 2020-04-02 Close